NCT07081373 Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.
| NCT ID | NCT07081373 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Condition | Anal Fistula |
| Study Type | INTERVENTIONAL |
| Enrollment | 408 participants |
| Start Date | 2025-07-16 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 408 participants in total. It began in 2025-07-16 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anal Fistula refers to an abnormal infectious fistula tract between the anorectum and the perianal skin. The prevalence of anal fistula is approximately 8.6 cases per 100,000 individuals. It can occur at any age but is relatively more common in individuals aged 20-40 years, with a higher incidence in males than females. Postoperative wound management is a critical component of the overall treatment for anal fistula patients. Regular postoperative wound care, such as dressing changes, can reduce recurrence rates, alleviate pain, and shorten hospitalization time. However, postoperative pain remains a major challenge in wound management following anal fistula surgery. This is largely attributed to inadequate current postoperative analgesic protocols. With ongoing advancements in local anesthetics, liposomal bupivacaine has been applied for postoperative analgesia. It offers higher bioavailability and a prolonged half-life, providing up to 72 hours of sustained analgesic effect. Given the limitations of existing analgesic strategies for post-anal fistula surgery, developing more effective pain management approaches to reduce postoperative pain holds significant clinical importance. Therefore, the investigators propose that a repeat-dosing strategy based on liposomal bupivacaine may provide superior postoperative pain control for anal fistula patients. To investigate this, the investigators designed a prospective, multicenter, randomized, open-label, controlled clinical trial. This study aims to evaluate the efficacy and safety of repeat-dose liposomal bupivacaine for postoperative analgesia following anal fistula surgery, thereby generating high-level evidence to support its clinical application in this context.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with anal fistula and scheduled to undergo anal fistula surgery; * Aged between 18 and 60 years; * ASA (American Society of Anesthesiologists) physical status class I-II; * Patient provides written informed consent after understanding the study protocol. Exclusion Criteria: * Anal fistula caused by specific etiologies (e.g., tuberculosis); * Concurrent acute perianal skin infection; * Poorly controlled diabetes (HbA1c \>9%); * Chronic use of corticosteroids; * History of radiotherapy or chemotherapy within the past 2 weeks; * Pregnancy or lactation; * Hypersensitivity to local anesthetics or any component of the investigational drug; * History of substance abuse, illicit drug use, or alcohol abuse; * Use or planned use of non-opioid/opioid analgesics within 12 hours before/during surgery; * Concurrent treatment with anticonvulsants, MAO inhibitors, antidepressants, neuromuscular blockers, or anticholinergics within 2 weeks prior to surgery; * Severe hepatic/renal impairment, cardiopulmonary dysfunction, coagulation disorders, or comorbidities contraindicating surgery; * History of severe psychiatric disorders or cognitive impairment; * Sensory disorders (e.g., hyperalgesia) or preexisting pain interfering with postoperative pain assessment; * Contraindications to amide-type local anesthetics, opioids, or propofol; * Participation in investigational drug trials within 90 days prior to enrollment; * Other clinical/laboratory conditions deemed by investigators to preclude trial participation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07081373 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Anal Fistula. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07081373 currently recruiting?
Yes, NCT07081373 is actively recruiting participants. Contact the research team at lhcheng@mail.sysu.edu.cn for enrollment information.
Where is the NCT07081373 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07081373 clinical trial?
NCT07081373 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. The trial plans to enroll 408 participants.